FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, gene engineering and immunology. There are disclosed HIV-1 gp41 binding single-chain triple-stranded alpha-coiled supercoiled molecules denoted as Alphabodies. There are also described nucleic acids coding the said Alphabodies, host cells containing the above nucleic acids, as well as pharmaceutical compositions containing the said Antibodies.
EFFECT: presented group of inventions can be used in medicine for treating, preventing and diagnosing HIV-infection.
16 cl, 16 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ROTAVIRAL PARTICLES WITH CHIMERIC SURFACE PROTEINS | 2014 |
|
RU2698049C2 |
| CONJUGATES CONSISTING OF POLYMER AND PEPTIDES DERIVING FROM gp41 HIV AND THEIR USING IN THERAPY | 2003 |
|
RU2317997C2 |
| PHARMACEUTICAL COMPOUNDS FOR OPTIMISED INJECTION OF gp41 HIV DERIVED PEPTIDES AND THEIR THERAPEUTIC APPLICATION | 2003 |
|
RU2357749C2 |
| NEW SOLUBLE AND STABILISED TRIMERIC FORM OF GP41 POLYPEPTIDES | 2004 |
|
RU2390525C2 |
| 5,15-BIS(4'-BIS-L-TYROSINYLAMIDOPHENYL)-10,20-BIS(N-METHYLPYRIDINIUM-3'-YL)PORPHIN DIOODIDE, SHOWING THE PROPERTY OF BINDING SARS-COV-2 VIRUS S-PROTEIN | 2022 |
|
RU2784940C1 |
| gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
| PHARMACEUTICAL AGENT FOR TREATMENT OF HIV-INFECTION, COMPOSITION CONTAINING THEREOF AND METHODS FOR ITS USING | 2002 |
|
RU2290197C2 |
| LIPOPEPTIDE FOR EFFECTIVE INHIBITION OF HIV, DERIVATIVE THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2017 |
|
RU2741123C1 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| IMMUNOREGULATORY VACCINE | 2013 |
|
RU2650709C2 |
